U.S. markets closed
  • S&P Futures

    4,411.25
    -3.75 (-0.08%)
     
  • Dow Futures

    34,977.00
    -21.00 (-0.06%)
     
  • Nasdaq Futures

    15,040.00
    -6.25 (-0.04%)
     
  • Russell 2000 Futures

    2,213.60
    -5.80 (-0.26%)
     
  • Crude Oil

    70.37
    -0.19 (-0.27%)
     
  • Gold

    1,815.80
    +1.70 (+0.09%)
     
  • Silver

    25.70
    +0.12 (+0.48%)
     
  • EUR/USD

    1.1875
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.1760
    +0.0020 (+0.17%)
     
  • Vix

    18.04
    -1.42 (-7.30%)
     
  • GBP/USD

    1.3930
    +0.0015 (+0.11%)
     
  • USD/JPY

    109.0600
    +0.0100 (+0.01%)
     
  • BTC-USD

    38,114.29
    -968.39 (-2.48%)
     
  • CMC Crypto 200

    932.88
    -10.56 (-1.12%)
     
  • FTSE 100

    7,105.72
    +24.00 (+0.34%)
     
  • Nikkei 225

    27,603.57
    -38.26 (-0.14%)
     

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Frequency Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 2, 2021 - (FREQ)

·1 min read

New York, New York--(Newsfile Corp. - July 21, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Frequency Therapeutics, Inc.

Shareholders who purchased shares of FREQ during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/frequency-therapeutics-inc-loss-submission-form/?id=17863&from=5

CLASS PERIOD: November 16, 2020 to March 22, 2021

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/90913